Obiettivo Patients with chronic inflammatory lung diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD) have a higher prevalence of respiratory infections. These infections accelerate disease progression and are associated with substantial morbidity and (especially in COPD) even mortality. Recent studies show that the airway microbiome of patients with asthma and COPD is different from that of healthy subjects. In murine lungs this has been shown to promote airway inflammation and loss of lung function. To this point it is unclear how changes in microbiome composition contribute to susceptibility for respiratory infections. Currently, treatment of patients with asthma and COPD is limited to symptom reduction and prevention of disease progression and hampered by the large amount of patients resistant to corticosteroid treatment. Understanding why these patients have an altered microbiome and increased susceptibility to respiratory infections is therefore pivotal to develop more effective healthcare strategies. Studies on host-microbiome interactions are mostly performed in murine models of airway diseases. Unfortunately, these models often fail to accurately reflect human disease. However, the recent development of Organ-on-a-Chip technology has effectively recapitulated many features of the modelled organ, thereby adding a level of complexity to cell cultures that is urgently needed. In contrast to existing airway epithelial cell cultures, these models contain several cell types, cultured at the air-liquid interface under a constant flow of air and nutrients while exposed to mechanical stress. However, also these cultures still lack an essential component of the airways: the airway microbiome. Therefore, the work described in this proposal aims to create an innovative human state-of-the-art Airway-on-Chip microbiome model to investigate the interaction of the airway epithelium with the microbiome and how this is linked to susceptibility for infection. Campo scientifico scienze mediche e della salutemedicina clinicapneumologiaasmascienze socialisociologiademografiamortalitàscienze naturaliscienze biologichemicrobiologiabatteriologiascienze mediche e della salutescienze della salutemalattie infiammatorieingegneria e tecnologiaaltre ingegnerie e tecnologiemicrotecnologiaorgano su chip Programma(i) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Argomento(i) MSCA-IF-2016 - Individual Fellowships Invito a presentare proposte H2020-MSCA-IF-2016 Vedi altri progetti per questo bando Meccanismo di finanziamento MSCA-IF-GF - Global Fellowships Coordinatore ACADEMISCH ZIEKENHUIS LEIDEN Contribution nette de l'UE € 162 864,60 Indirizzo Albinusdreef 2 2333 ZA Leiden Paesi Bassi Mostra sulla mappa Regione West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Altri finanziamenti € 0,00 Partner (1) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto Partner Le organizzazioni partner contribuiscono all’attuazione dell’azione, ma non sottoscrivono l’accordo di sovvenzione. EMULATE INC Stati Uniti Contribution nette de l'UE € 0,00 Indirizzo 27 drydock avenue 5th floor 02210 Boston Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Altri finanziamenti € 80 065,20
